Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all‑cash transaction that values the endocrine specialist at about $10 dollars. Under the terms of the definitive agreement, Vertex will pay $85 per Crinetics share, with the deal valued at roughly $8.8 billion net of cash on hand, and closing targeted for the third quarter of 2026 subject to regulatory and shareholder approvals. Also read: CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight

HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication. The decision allows oncologists to use Orpathys in adults with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma whose tumours harbor MET amplification and who have already been through at least two systemic treatment regimens. Also read: CVS Pharmacy Joins Medicare